Management of fungal infection in neutropenic patients with fluconazole.
Fluconazole is a new orally absorbed antifungal azole which is effective in the treatment of mucosal and systemic infections caused by Candida, cryptococci and other fungi. In view of its favourable efficacy, safety and pharmacokinetic profile it was considered appropriate to evaluate its use prophylactically in patients undergoing a period of neutropenia. Two hundred and forty-eight patients receiving chemotherapy and/or bone marrow transplantation for the treatment of acute leukaemia, lymphoma or aplastic anaemia, and expected to be rendered temporarily neutropenic, have been entered into an ongoing multicentre comparative clinical study to compare the prophylactic efficacy of 50 mg daily oral fluconazole with that of widely used regimens of oral polyenes. The incidence of suspected fungal infection was less in the fluconazole group (27%) than in the polyene group (45%), the difference being statistically significant (P less than 0.05). Only one of the suspected infections in the fluconazole group was confirmed mycologically compared with 17 in the polyene group. Fluconazole prophylaxis was well tolerated and it therefore offers a promising new approach to the management of fungal infection in the neutropenic patient. Further studies are warranted to define the optimum dosage for use in this situation.
Brammer
K W
KW
Clinical Research Department, Pfizer Central Research, Sandwich, Kent, UK.
D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D015725:Fluconazole / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications*; D011090:Polyenes / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D011090:Polyenes; D015725:Fluconazole